Pharmafile Logo

Peter Impey

- PMLiVE

Medscape’s Impact on Women’s Health Education: Key Publications at ISSWSH 2025 & Beyond

Just in time for Women’s History Month and International Women’s Day on March 8th, Medscape is proud to showcase its dedication to advancing women's health education. Sara Thorpe, MPH, Director,...

Medscape Education

Embracing Webcams in Virtual Meetings – Building Company Culture Virtually

Tired of the disconnect in virtual meetings? Discover how using webcams can enhance communication, build stronger relationships, and create a more engaging work environment.

Impetus Digital

- PMLiVE

Eli Lilly unveils plans to invest $27bn in four new US manufacturing sites

The investment raises the company’s total US capital expansion commitments to more than $50bn since 2020

EU flag

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The drug has been approved for rheumatoid arthritis, giant cell arteritis and other indications

- PMLiVE

Why local knowledge is key to global pharmacovigilance outcomes

The challenge for companies is to ensure their local affiliates meet local PV obligations while staying aligned with global PV requirements

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study

More than two million cases of the disease were diagnosed globally in 2022

- PMLiVE

J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

Inflammatory bowel disease affects almost one in every 100 people in the US

- PMLiVE

NHS England appoints Sir James Mackey as CEO

Mackey is currently serving as chief executive of Newcastle Hospitals NHS Foundation Trust

- PMLiVE

FDA approves Mirum’s Ctexli as first treatment for rare lipid storage disease CTX

The progressive genetic disorder affects up to 2,000 people in the US

- PMLiVE

NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links